Prognostic Index for Acute- and Lymphoma-Type Adult T-Cell Leukemia/Lymphoma
- 10 May 2012
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (14), 1635-1640
- https://doi.org/10.1200/jco.2011.38.2101
Abstract
Purpose: The prognosis of acute- and lymphoma-type adult T-cell leukemia/lymphoma (ATL) is poor, but there is marked diversity in survival outcomes. The aim of this study was to develop a prognostic index (PI) for acute- and lymphoma-type ATL (ATL-PI). Patients and Methods: In a retrospective review, data from 807 patients newly diagnosed with acute- and lymphoma-type ATL between January 2000 and May 2009 were evaluated. We randomly divided subjects into training (n = 404) and validation (n = 403) samples, and developed a PI using a multivariable fractional polynomial model. Results: Median overall survival time (MST) for the 807 patients was 7.7 months. The Ann Arbor stage (I and II v III and IV), performance status (0 to 1 v 2 to 4), and three continuous variables (age, serum albumin, and soluble interleukin-2 receptor [sIL-2R]) were identified as independent prognostic factors in the training sample. Using these variables, a prognostic model was devised to identify different levels of risk. In the validation sample, MSTs were 3.6, 7.3, and 16.2 months for patients at high, intermediate, and low risk, respectively (P < .001; χ2 = 89.7, 2 df; log-rank test). We also simplified the original ATL-PI according to dichotomizing age at 70 years, serum albumin at 3.5 g/dL, and sIL-2R at 20,000 U/mL and developed an easily calculable PI with prognostic discrimination power (P < .001; χ2 = 74.2, 2 df; log-rank test). Conclusion: The ATL-PI is a promising new tool for identifying patients with acute- and lymphoma-type ATL at different risks.Keywords
This publication has 25 references indexed in Scilit:
- Definition, Prognostic Factors, Treatment, and Response Criteria of Adult T-Cell Leukemia-Lymphoma: A Proposal From an International Consensus MeetingJournal of Clinical Oncology, 2009
- Treatment of adult T‐cell leukemia/lymphoma: past, present, and futureEuropean Journal of Haematology, 2007
- VCAP-AMP-VECP Compared With Biweekly CHOP for Adult T-Cell Leukemia-Lymphoma: Japan Clinical Oncology Group Study JCOG9801Journal of Clinical Oncology, 2007
- Human T lymphotropic virus type-I and adult T-cell leukemia in JapanInternational Journal of Hematology, 2002
- A new G‐CSF‐supported combination chemotherapy, LSG15, for adult T‐cell leukaemia‐lymphoma: Japan Clinical Oncology Group Study 9303British Journal of Haematology, 2001
- Major prognostic factors of patients with adult T-cell leukemia-lymphoma: A cooperative studyLeukemia Research, 1991
- Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphomaBritish Journal of Haematology, 1991
- Modelling the risk of adult T‐cell leukemia/lymphoma in persons infected with human T‐lymphotropic virus type IInternational Journal of Cancer, 1989
- Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphomaProceedings of the National Academy of Sciences of the United States of America, 1980
- Adult T-cell leukemia: clinical and hematologic features of 16 casesPublished by American Society of Hematology ,1977